Compare GYGY & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GYGY | LGVN |
|---|---|---|
| Founded | 2 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 21.4M |
| IPO Year | 2026 | 2021 |
| Metric | GYGY | LGVN |
|---|---|---|
| Price | $0.45 | $2.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.25 |
| AVG Volume (30 Days) | ★ 3.4M | 145.6K |
| Earning Date | 11-20-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | $46.15 |
| Revenue Next Year | N/A | $396.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.47 | $0.48 |
| 52 Week High | $11.81 | $7.60 |
| Indicator | GYGY | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 15.04 | 39.08 |
| Support Level | N/A | $2.30 |
| Resistance Level | $1.27 | $7.30 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | 0.08 | -0.10 |
| Stochastic Oscillator | 1.25 | 17.69 |
Game Your Game Inc develops and markets AI-based sports performance tracking technology that is prominently focused on the golf industry. Its products include GPS shot tracking hardware, AI algorithms, and a smart coaching app to provide players with real-time insights, recommendations, and personalized performance analytics. The company's technology consists of the GameGolf KZN AI platform, which is an integrated golf performance ecosystem of proprietary shot-tracking hardware and subscription-based software solutions. It generates revenue from the sale of KZN AI hardware device and from recurring annual subscription fees for continued access to the GameGolf App, GameGolf Smart Caddie and the GameGolf platform. Geographically, the company operates mainly in the United States and Europe.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.